Ayşe Esra Manguoğlu

Ayşe Esra Manguoğlu

Auto-generated profile, based on publicly available information

Ayşe Esra Manguoğlu

Department of Medical Biology, Faculty of Medicine, Akdeniz University, Antalya, Turkey

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in Cancer Genetics and Cytogenetics
Verified
Journal Article
Closed access
EMEsra Manguoğlu
Esra Manguoğlu
ŞGŞefik Güran
Şefik Güran
DYDeniz Yamaç
Deniz Yamaç
TÇTaner Çolak
Taner Çolak
MŞMehmet Şimşek
Mehmet Şimşek
GLGüven Lüleci
Güven Lüleci

1 June 2019 in Gene
Verified
Journal Article
Closed access
GKGamze Koçak
Gamze Koçak
BGBanu Nur Güzel
Banu Nur Güzel
EMErcan Mıhçı
Ercan Mıhçı
OKOsman Alphan Kupesiz
Osman Alphan Kupesiz
KYKoray Yalcin
Koray Yalcin
AMAyşe Esra Manguoğlu
Ayşe Esra Manguoğlu

3 May 2024 in Expert Review of Endocrinology & Metabolism
Verified
Journal Article
Closed access
AAAsef Azad
Asef Azad
HAHasan Ali Altunbas
Hasan Ali Altunbas
AMAyse Esra Manguoglu
Ayse Esra Manguoglu
IntroductionType 1 diabetes (T1D) mellitus is an autoimmune disease in which immune cells, predominantly effector T cells, destroy insulin-secreting beta-cells. Beta-cell destruction led to various consequences ranging from retinopathy and nephropathy to neuropathy. Different strategies have been developed to achieve normoglycemia, including exogenous glucose compensation, whole pancreas transplantation, islet transplantation, and beta-cell replacement.Areas coveredThe last two decades of experience have shown that indigenous glucose compensation through beta-cell regeneration and protection is a peerless method for T1D therapy. Tremendous studies have tried to find an unlimited source for beta-cell regeneration, on the one hand, and beta-cell protection against immune attack, on the other hand. Recent advances in stem cell technology, gene editing methods, and immune modulation approaches provide a unique opportunity for both beta-cell regeneration and protection.Expert opinionPluripotent stem cell differentiation into the beta-cell is considered an unlimited source for beta-cell regeneration. Devising engineered pancreas-specific regulatory T cells using Chimeric Antigen Receptor (CAR) technology potentiates an effective immune tolerance induction for beta-cell protection. Beta-cell regeneration using pluripotent stem cells and beta-cell protection using pancreas-specific engineered regulatory T cells promises to develop a curative protocol in T1D.

28 August 2004
Verified
Journal Article
Closed access
ASAkin Sevinç
Akin Sevinç
DYDrakoulis Yannoukakos
Drakoulis Yannoukakos
IKIrene Konstantopoulou
Irene Konstantopoulou
EMEsra Manguoglu
Esra Manguoglu
GLGüven Lüleci
Güven Lüleci
TOTayfun Ozçelik
Tayfun Ozçelik

1 November 2023 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Verified
Journal Article
Closed access
AAAsef Azad
Asef Azad
ÜGÜmmü Rana Gökmen
Ümmü Rana Gökmen
HUHilmi Uysal
Hilmi Uysal
SKSadi Koksoy
Sadi Koksoy
Ugur BilgeUgur Bilge
Ugur Bilge
AMAyşe Esra Manguoğlu
Ayşe Esra Manguoğlu
Objective: Neuroinflammation is the hallmark of amyotrophic lateral sclerosis (ALS) disease. Regulatory T cells (Tregs) are essential in immune tolerance and neuroinflammation prevention. It has been shown that a significant decrease in Treg and FoxP3 protein expression is observed in ALS patients. The main reason for the FoxP3(+) Treg loss in ALS is unknown. In this study, the role of autophagy dysregulation in FoxP3(+) Tregs in ALS was investigated.Methods: Twenty-three ALS patients and 24 healthy controls were recruited for the study. Mononuclear cells (MNCs) were obtained from peripheral blood, and then Tregs were isolated. Isolated Tregs were stained with FoxP3 and LC3 antibodies and analyzed in flow cytometry to determine autophagy levels in FoxP3(+) Tregs in patients and controls.Results: The mean of FoxP3(+) LC3(+) cells, were 0.47 and 0.45 in patients and controls, respectively. The mean of FoxP3(+) LC3- cells was 0.15 in patients and 0.20 in controls, p = 0.030 (p < 0.05). There is no significant correlation between ALSFRS-R decay rate and autophagy level in patients. Also, there is no significant difference between autophagy levels in FoxP3(+) Tregs in patients with rapidly progressing ALS and slow-progressing ALS.Conclusion: Excessive autophagy levels in FoxP3(+) Tregs in ALS patients can potentially be an explanation for an increased cell death and result in worsened neuroinflammation and disease onset. However, the disease progress is not attributable to autophagy levels in FoxP3(+) Tregs.

1 January 2011 in Balkan Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
EME Manguoğlu
E Manguoğlu
SAS Akdeniz
S Akdeniz
NDN Dündar
N Dündar
ÖDÖ Duman
Ö Duman
BAB Aktekin
B Aktekin
GLG Lüleci
G Lüleci
RLIP76Gene Variants are not Associated with Drug Response in Turkish Epilepsy Patients: Approximately 30% of epileptic patients remain untreated, in spite of trials with maximum tolerable doses of more than one drug. The RalA binding protein 1 (RALBP1/RLIP76), a multifunctional, anti-apoptotic, multidrug transporter protein, has been proposed as being responsible for the drug resistance mechanism in epilepsy. We have investigated polymorphic differences in the coding regions and exon-intron boundaries of theRLIP76gene, between 146 refractory and 155 non refractory epileptic patients in Turkey, using denaturing high performance liquid chromatography (HPLC) and sequencing analysis techniques. We have detected the following sequence variants: c.160-4G>A, c.187C>G, c.1562-38G>A, c.1670+107G>A, c.1670+93G>A, c.1670+96G>A, c.1670+100C>T, c.1670+130C>T, c.1670+131G>C, c.1670+140 G>C, and found no statistically significant correlation between allele frequencies and drug response status. We conclude that sequence variants of this gene are not involved in drug resistance in epilepsy.